16 completed, 2 terminated, 1 withdrawn. 16 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 13, Terminated 2, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Completed 1 |
Follow PROSTVAC: new trials by email Literature Review of PROSTVAC trials Research Report on PROSTVAC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer MVA-BN-Brachyury - Prostate Adenocarcinoma | Phase 2 | Withdrawn | University of Utah | 2019-11-20 | 2021-09-22 | |
| Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer PROSTVAC-V, PROSTVAC-F, Nivolumab - Metastatic Hormone-Sensitive Prostate Cancer | Phase 1 | Completed | Washington University School of Medicine | 19 | 2018-09-14 | 2022-08-05 |
| Combination Immunotherapy in Biochemically Recurrent Prostate Cancer Antigen direct immunotherapy: PROSTVAC-V, Antigen direct immunotherapy: PROSTVAC-F, MSB0011359C (M7824) - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2018-03-20 | 2025-06-19 |
| Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer PROSTVAC-V, PROSTVAC-F, Docetaxel - Prostate Cancer, Prostate Neoplasms | Phase 2 | Completed | National Cancer Institute (NCI) | 74 | 2016-01-19 | 2026-04-29 |
| Prostvac in Patients With Biochemically Recurrent Prostate Cancer PROSTVAC -V, PROSTVAC-F - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 97 | 2015-12-22 | 2022-11-14 |
| PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec - Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 154 | 2015-06-03 | 2023-07-19 |
| Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM, PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM, Enzalutamide - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 57 | 2013-08-12 | 2023-09-26 |
| Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer PROSTVAC-F (Fowlpox)/TRICOM, PROSTVAC-V (Vaccinia)/TRICOM, Enzalutamide (Xtandi) - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 38 | 2013-07-22 | 2020-09-16 |
| A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer PROSTVAC-V, PROSTVAC-F, GM-CSF - Prostate Cancer Metastatic | Phase 3 | Completed | Bavarian Nordic | 1297 | 2011-11-28 | 2019-09-04 |
| Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Docetaxel, Laboratory Biomarker Analysis, Prednisone - Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 10 | 2010-08-01 | 2017-09-19 |
| Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 64 | 2007-02-23 | 2018-11-29 |
| A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer Bicalutamide, Goserelin Acetate, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine - Recurrent Prostate Carcinoma, Stage I Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 50 | 2006-02-01 | 2015-06-30 |
| Sequential Vaccinations in Prostate Cancer Patients Recombinant Fowlpox-GM-CSF, Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM), Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM) - Prostatic Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2003-05-22 | 2017-10-26 |
| Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 2002-08-01 | 2013-06-19 | |
| PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer rV-PSA, rF-PSA, rV-B7.1 - Prostate Cancer, Prostate Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2000-06-13 | 2017-07-02 |
| Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer aldesleukin, recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 2000-06-01 | 2015-04-29 | |
| Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, laboratory biomarker analysis - Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 86 | 2000-01-01 | 2013-01-24 |
| PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer fowlpox virus vaccine vector, recombinant vaccinia prostate-specific antigen vaccine - Prostate Cancer | Phase 2 | Completed | Eastern Cooperative Oncology Group | 60 | 1999-09-24 | 2023-06-22 |
| A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate PROSTVAC - Prostatic Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 75 | 1994-03-01 | 2008-03-04 |
Prostatic Neoplasms (16) · Neoplasm Metastasis (1)
National Cancer Institute (NCI) (15) · Bavarian Nordic (1) · Eastern Cooperative Oncology Group (1) · University of Utah (1) · Washington University School of Medicine (1)
United States (19) · Australia (1) · Belgium (1) · Canada (1) · Denmark (1) · Estonia (1) · France (1) · Germany (1) · Iceland (1) · Israel (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · Russia (1) · Spain (1)
Ravi A Madan, M.D. (5) · Philip M. Arlen, MD (2) · Douglas McNeel (1) · Howard L. Kaufman, MD (1) · James L Gulley, M.D. (1) · James L. Gulley, MD (1) · John K Parsons (1) · Joseph Paul Eder (1) · Melissa Abel, M.D. (1) · Philip Kantoff, MD (1) · Robert DiPaola (1) · Russell Pachynski, M.D. (1)
PMID 15169798, PMID 16006888, PMID 16489082, PMID 17707059, PMID 18628467, PMID 22932804, PMID 30197041, PMID 30817251, PMID 33664086, PMID 37134294
U10CA021115 (2), N01CN00031 (1), P30CA023074 (1), U01CA062490 (1), U10CA180820 (1)